21 / 83
P
rimary
osteosarcoma
of
the
breast
:
pathological
and
imaging
findings
R
ev
A
ssoc
M
ed
B
ras
2015; 61(6):497-499
499
Patients with large (> 5cm) and/or high-grade tumors
may benefit from chemotherapy, using drugs such as
doxorubicin, cisplatin, methotrexate, and ifosfamide that
show anti-tumor activity in osteosarcoma.
6
It is worth
mentioning that chemotherapy has toxicity that may re-
sult in death.
7
This aspect needs to be taken into consid-
eration in therapeutic planning.
R
esumo
Osteossarcoma primário da mama: achados patológicos
e de imagem.
O osteossarcoma primário da mama (OPM) é um tumor
extremamente raro e agressivo. O diagnóstico diferencial
do OPM inclui o osteossarcoma da parede torácica e o
carcinoma metaplásico da mama. Exames de imagem que
excluam a existência de uma conexão direta entre o tu-
mor e a parede torácica, e estudos histopatológico e imu-
no-histoquímico que descartem a presença de um com-
ponente epitelial são necessários para o diagnóstico de
OPM. Relatamos um caso de OPM em uma mulher de
69 anos de idade. Os achados de imagem e patológicos
são apresentados. A abordagem terapêutica é discutida à
luz do conhecimento atual, incluindo potenciais compli-
cações.
Palavras-chave:
mama, neoplasias da mama, sarcoma,
imuno-histoquímica.
R
eferences
1.
Szajewski M, Kruszewski WJ, Ciesielski M, Smiałek-Kusowska U, Czerepko
M, Szefel J. Primary osteosarcoma of the breast: A case report. Oncol Lett.
2014;7:1962-4.
2.
Silver SA, Tavassoli FA. Primary osteogenic sarcoma of the breast: a
clinicopathologic analysis of 50 cases. Am J Surg Pathol 1998;22:925-33.
3.
Remadi S, Doussis-Anagnostopoulu I, Mac Gee W. Primary osteosarcoma
of the breast. Pathol Res Pract. 1995;191:471-4.
4. Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma:
clinicopathologic series from the Mayo Clinic and review of the literature.
Br J Cancer. 2004;91:237-41.
5.
McGowan TS, Cummings BJ, O’Sullivan B, Catton CN, Miller N, Panzarella
T. An analysis of 78 breast sarcoma patients without distant metastases at
presentation. Int J Radiat Oncol Biol Phys. 2000;46:383-90.
6.
ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 2014;25 Suppl 3:iii113-23.
7. Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, et al.
Benefits and adverse events in younger versus older patients receiving
neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.
J Clin Oncol. 2013;31:2303-12.
FIGURE 3
Pathology findings. (A) Immature mesenchymal bone-forming neoplasm (HE, 40x); (B) atypical spindle-cell neoplasm and
immature osteoid matrix (HE, 200x); (C) mesenchymal neoplasm producing osteoid matrix surrounded by osteoclast-like giant cells and atypical
mesenchymal cells (HE, 400x); (D) osteoclast-like giant cells were CD68-positive (200x) (arrows).
A
B
C
D